DeLLPhi-304

Lung Cancer

DeLLPhi-304

About the TROPION-Lung01 Trial

In TROPION-Lung01, a Phase 3, randomized, open-label trial presented at the 2024 World Conference on Lung Cancer (WCLC24) in San Diego, CA, investigators evaluated datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of actionable genomic alterations. Eligible patients had stage IIIB, IIIC, or IV NSCLC, an ECOG performance status of 0 or 1, and no prior exposure to docetaxel. Participants were randomized to receive either Dato-DXd 6 mg/kg or docetaxel 75 mg/m², both administered every three weeks. Stratification was based on histology, presence of actionable genomic alterations, and prior anti–PD-(L)1 monoclonal antibody therapy. The primary endpoints were progression-free survival (PFS) assessed by blinded independent central review and overall survival (OS), with key secondary endpoints including objective response rate (ORR), duration of response (DoR), and safety. Dato-DXd demonstrated a statistically significant improvement in PFS compared to docetaxel. While OS favored Dato-DXd numerically, the difference did not reach statistical significance. The safety profile of Dato-DXd was manageable and consistent with prior findings, though some grade 5 interstitial lung disease (ILD) events were reported. Safety data were presented by Dr. Aaron Lisberg, with final OS results discussed by Dr. Jacob Sands. Additional expert commentary was shared via social media by Drs. Yakup Ergün, Timothée Olivier, Prunella Blinman, and the Oncology Brothers.

Table of Contents

Major Presentations and Milestones

DeLLphi-304 Trial design, results, and conclusions

DeLLphi-304 Sentiments and Criticisms

DeLLphi-304 Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

DeLLphi-304 Trial: Major Presentations and Milestones

Primary speakers driving the story

At ASCO 2025, Charles M. Rudin, MD, PhD presented the phase 3 DeLLphi‑304 trial: tarlatamab (DLL3 T‑cell engager) versus investigator’s‑choice chemotherapy in previously treated small‑cell lung cancer (SCLC). Publication was concurrent in the New England Journal of Medicine (NEJM), and expert coverage emphasized a statistically significant overall survival (OS) benefit, with supportive progression‑free survival (PFS), favorable patient‑reported outcomes (PROs), and a manageable cytokine‑release syndrome (CRS) profile.

NEJM signposted the phase 3 results and safety profile at the time of the oral presentation.

Hidehito Horinouchi, MD underscored the OS advantage with precise figures and the ASCO oral context (presenter: Charles M. Rudin).

DeLLphi-304 Trial Design, Results, and Conclusions

Trial Design:

DeLLphi‑304 is a phase 3, randomized, controlled study in previously treated SCLC after first‑line platinum‑based chemotherapy with or without prior anti‑PD‑(L)1. Patients (ECOG 0–1) were randomized 1:1 to tarlatamab versus investigator’s‑choice chemotherapy (topotecan or amrubicin; lurbinectedin permitted in some regions). Asymptomatic, treated or untreated brain metastases were allowed. Stratification included prior anti‑PD‑(L)1 exposure, chemotherapy‑free interval, brain metastases status, and intended chemotherapy. The primary endpoint was OS; key secondary endpoints included PFS and PROs; other secondary endpoints included ORR, DCR, DOR, and safety.

Primary Results:

OS favored tarlatamab with a hazard ratio of 0.60 (95% CI 0.47–0.77); median OS 13.6 vs 8.3 months. PFS also favored tarlatamab (reported HR approximately 0.71), with KOLs citing median PFS around 4.2 months for tarlatamab versus roughly 3.2–3.7 months for chemotherapy. Multiple posts noted a higher ORR (~35% vs 20%) and improved PROs with tarlatamab. Benefit was observed in both chemotherapy‑resistant and chemotherapy‑sensitive subgroups, with broad consistency across prespecified strata shared from ASCO slides.

Safety:

Grade ≥3 treatment‑related adverse events were lower with tarlatamab compared with chemotherapy (27% vs 62% in one summary). CRS was largely low‑grade (reported distribution: grade 1 42%, grade 2 13%, grade 3 1%). No grade 4/5 CRS events were highlighted in shared summaries. KOLs noted logistical complexity (monitoring for CRS and related immune toxicities) but emphasized that adverse events were generally manageable with established mitigation protocols.

Key Conclusions:

The phase 3 DeLLphi‑304 trial demonstrates that tarlatamab improves OS versus investigator’s‑choice chemotherapy in previously treated SCLC, with supportive PFS, higher response rates, and better PROs. Safety signals were characterized by predominantly low‑grade CRS and a lower rate of grade ≥3 TRAEs versus chemotherapy. KOLs converged on tarlatamab as a new 2L standard of care, while emphasizing implementation considerations (CRS pathways, infusion logistics, and access).

DeLLphi-304 Sentiments and Criticisms

Positive Reception:

Misty Dawn Shields, MD: "Tarlatamab is NOW the 2L standard of care for ES-SCLC! mOS: 13.6 tarla vs 8.3 mo chemo, HR 0.6" https://x.com/drshieldsmd/status/1929527021249458449

Eric K. Singhi, MD: "Primary endpoint of OS met in #DeLLphi304. ✅ HR 0.60 favoring tarlatamab over chemotherapy ✅ Benefit noted BOTH in chemotherapy-resistant and chemotherapy-sensitive groups" https://x.com/lungoncdoc/status/1929667751494439206

NEJM (concurrent publication): "tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events." https://x.com/NEJM/status/1929510565325709500

Critical Perspectives:

Tom Newsom‑Davis, MD highlighted operational complexity and access: "AE: CRS & ICONs challenging … Complex to give & monitor … Need [UK] access" https://x.com/tnewsomdavis/status/1929668862598926624

Jyoti Malhotra, MD emphasized equitable uptake: "Yes excited to see these results- now we have to work on making it accessible to all patients" https://x.com/JyotiMalhotraMD/status/1929586696556794014

DeLLphi-304 Temporal Sentiment Arc

2023–2024 (Pre‑phase 3 anticipation)

Primary/KOL tweets:

June 2025 (ASCO25 oral presentation and NEJM publication)

Primary/KOL tweets:

Post‑meeting amplification (June 2025)

Overall, the discourse progressed from anticipation of DLL3 T‑cell engagers to definitive phase 3 validation with OS benefit, followed by pragmatic focus on toxicity pathways (CRS) and regional access considerations as tarlatamab is positioned as the 2L standard for relapsed SCLC.

DeLLphi-304 Professional Resources